Prosensa 'happy' to regain drisapersen from GSK; stock falls
This article was originally published in Scrip
Executive Summary
Prosensa CEO Hans Schikan says the Dutch company is "happy" to have regained control of drisapersen from GlaxoSmithKline, because Prosensa can focus on the appropriate path forward after the Duchenne muscular dystrophy (DMD) drug failed in a Phase III clinical trial.